Home> Products> Inhibitors> FT011-CAS 1001288-58-9
price inquiry for CAS:1001288-58-9, Product:FT011
For research use only. We do not sell to patients.

FT011 CAS: 1001288-58-9

Category: Inhibitors
Product Name: FT011
Cat No: I000070
CAS No: 1001288-58-9
Molecular Formula: C20H17NO5
Molecular Weight: 351.35
Solubility: DMSO ≥ 29 mg/mL
CAS 1001288-58-9,FT011
  • Description

FT011, a new anti-fibrotic and an anti-inflammatory agent, prevents glycogen accumulation by reducing glycogenin mRNA translation.
In vitro: FT011 do not change glycogen synthase or glycogen phosphorylase enzyme activities but prevent both glycogenin mRNA synthesis and accumulation of Armanni-Ebstein lesions in the diabetic kidney. [1] FT011 inhibited both TGF-1 and PDGF-BB induced collagen production as well as PDGF-BB-mediated mesangial proliferation. FT011 reduced albuminuria, glomerulosclerosis and tubulointerstitial fibrosis. [3]
In vivo: The reference for FT011 is 200 mgkg1day1 [1]. rats are studied for 8 and 32 weeks and receiving intravitreal injections of FT011 (50 μM). FT011 reduces etinal leukostasis, microglial density and mRNA levels of intercellular adhesion molecule-1 (ICAM-1). Late intervention with FT011 reducesacellular capillaries and the elevated mRNA levels of collagen IV and fibronectin in diabetic rats. [2]

  • References


[1]. Lau X Attenuation of Armanni-Ebstein lesions in a rat model of diabetes by a new anti-fibrotic, anti-inflammatory agent, FT011. Diabetologia. 2013 Mar;56(3):675-9.
[2]. Deliyanti D et al. FT011, a Novel Cardiorenal Protective Drug, Reduces Inflammation, Gliosis and Vascular Injury in Rats with Diabetic Retinopathy. PLoS One. 2015 Jul 29;10(7):e0134392.
[3]. Gilbert RE et al. A purpose-synthesised anti-fibrotic agent attenuates experimental kidney diseases in the rat. PLoS One. 2012;7(10)


price inquiry for CAS:1001288-58-9, Product:FT011